02.05.2007 11:00:00
|
Millipore Announces New Chief Financial Officer
Millipore Corporation (NYSE:MIL), a leading provider of products and
services that improve productivity and results in biopharmaceutical
manufacturing and in clinical, analytical and research laboratories,
today announced that Charles Wagner has been appointed to succeed
Kathleen Allen as the Company’s Chief
Financial Officer (CFO). Mr. Wagner will assume the role on August 15,
2007, and Ms. Allen will stay on with Millipore through February 18,
2008 to assist with the transition.
"After more than 23 years with Millipore and
seven as our CFO, Kathy has decided it is time to pursue life outside of
the Company,” said Martin Madaus, Chairman &
CEO of Millipore. "During Kathy’s
long and successful career at Millipore, she has made tremendous
contributions to the success of the company. She has built a strong
finance organization, an excellent internal control environment, and a
talented IT organization. While we are sorry to see Kathy leave, we wish
her the very best in her future endeavors.
"We are well positioned with a ready successor
in Charlie Wagner. He has been a key architect of our new strategic
direction and he has spearheaded our successful M&A activities over the
past two years. Most recently, Charlie has led the substantial
company-wide program to integrate Serologicals into Millipore. Charlie
brings great skills and experience to the CFO role, and we are planning
for a smooth transition as we execute our exciting growth strategy.”
Mr. Wagner is currently the Vice President, Strategy and Corporate
Development for Millipore. He holds a Bachelor of Science degree in
accounting from Boston College, and began his career in public
accounting at Coopers & Lybrand. Mr. Wagner also worked in Corporate
Finance for Millipore before obtaining his Master of Business
Administration degree from Harvard University. Later, he advised
companies on growth strategy and acquisitions as a Manager and
Consultant for Bain & Company before rejoining Millipore in 2002 to head
the company’s strategy and corporate
development activities.
Quarterly Earnings Call
Millipore will host a conference call and webcast to discuss its
financial results, business outlook, and related corporate and financial
matters at 4:45 p.m. Eastern Time today. The call can be accessed
through Millipore’s website: http://www.millipore.com.
A replay of the call will be archived on the Investor Relations section
of the website and will also be available via telephone by dialing (800)
642-1687 or (706) 645-9291 and entering confirmation code: 3836444. The
telephonic replay will be available beginning at 8:00 p.m. ET on May 2,
2007 until 11:59 p.m. ET on May 5, 2007.
About Millipore
Millipore is a leading provider of products and services that improve
productivity and results in biopharmaceutical manufacturing and in
clinical, analytical and research laboratories. The Company is organized
in two operating divisions. Its Bioprocess Division helps pharmaceutical
and biotechnology companies to optimize their manufacturing
productivity, ensure the quality of drugs, and scale up the production
of difficult-to-manufacture biologics. Its Bioscience Division helps
optimize laboratory productivity and workflows by providing reagents,
kits and other enabling technologies and products for life science
research and development. Millipore has a deep understanding of its
customers' research and manufacturing process needs, and offers reliable
and innovative tools, technologies and services. The Company is part of
the S&P 500 Index and employs approximately 6,000 employees worldwide.
For additional information on Millipore Corporation, please visit its
website at: www.millipore.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Merck KGaAmehr Nachrichten
01.02.25 |
EU-Pharmasektor im Aufwind? Analysten bullish auf Merck, Roche & Co. (finanzen.at) | |
31.01.25 |
Börse Frankfurt in Grün: LUS-DAX legt letztendlich zu (finanzen.at) | |
31.01.25 |
Börse Frankfurt: DAX fällt zum Handelsende (finanzen.at) | |
31.01.25 |
Handel in Frankfurt: DAX nachmittags mit Zuschlägen (finanzen.at) | |
31.01.25 |
Starker Wochentag in Frankfurt: Börsianer lassen LUS-DAX am Freitagnachmittag steigen (finanzen.at) | |
31.01.25 |
ANALYSE-FLASH: Deutsche Bank Research senkt Ziel für Merck KGaA - 'Buy' (dpa-AFX) | |
31.01.25 |
Zuversicht in Frankfurt: LUS-DAX präsentiert sich mittags fester (finanzen.at) | |
31.01.25 |
Freundlicher Handel in Frankfurt: DAX fester (finanzen.at) |
Analysen zu Merck KGaAmehr Analysen
31.01.25 | Merck Buy | Deutsche Bank AG | |
20.01.25 | Merck Overweight | JP Morgan Chase & Co. | |
17.01.25 | Merck Overweight | JP Morgan Chase & Co. | |
09.01.25 | Merck Buy | Goldman Sachs Group Inc. | |
07.01.25 | Merck Market-Perform | Bernstein Research |
Aktien in diesem Artikel
Merck KGaA | 144,40 | -1,16% |
Indizes in diesem Artikel
S&P 500 | 6 040,53 | -0,50% |